What one share of Renovorx holds
We are a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (“FDA”)-cleared local drug-delivery device, targeting high unmet medical needs.
Renovorx’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$0.31 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.30 |
| Cash and investments | $0.21 |
| Book value | $0.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$1.72 | — | — | — | −$6.56 |
| 2021 | — | −$1.21 | — | — | — | $1.72 |
| 2022 | — | −$1.09 | — | — | — | $0.68 |
| 2023 | — | −$0.99 | — | — | — | $0.28 |
| 2024 | $0.00 | −$0.40 | $0.00 | −$0.41 | — | $0.19 |
| 2025 | $0.03 | −$0.32 | $0.00 | −$0.31 | — | $0.15 |
Common questions about Renovorx
How much does one share of Renovorx earn?
Over the last 12 months, Renovorx lost $0.31 for each share on $0.05 of sales.
Does Renovorx pay a dividend?
Renovorx didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Renovorx’s book value per share?
Renovorx’s book value is $0.20 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Renovorx have?
Each share of Renovorx has $0.21 of cash and investments, as of June 30, 2026.
What is Renovorx’s free cash flow per share?
−$0.30 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Renovorx bought back shares?
Renovorx’s share count rose about 1496% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.